Program Against Cancer Therapeutic Resistance (ProCure), IDIBELL
Spain
1 December 2019 - 30 November 2020
Principal institution: Bellvitge Biomedical Research Institute (IDIBELL)
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for Program Against Cancer Therapeutic Resistance (ProCure), IDIBELL published between 1 December 2019 - 30 November 2020 which are tracked by the Nature Index.
Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
| Count | Share |
|---|---|
| 6 | 0.36 |
Outputs by subject (Share)
| Subject | Count | Share | |
|---|---|---|---|
| Life Sciences | 6 | 0.36 | |
Top articles by Altmetric score in current window
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics
2020-01-07
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
Nature Communications
2020-06-22
Zonation of Ribosomal DNA Transcription Defines a Stem Cell Hierarchy in Colorectal Cancer.
Cell Stem Cell
2020-05-10
Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1.
Cell Metabolism
2020-05-05
Requirement for epithelial p38α in KRAS-driven lung tumor progression
Proceedings of the National Academy of Sciences of the United States of America
2020-01-22
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
